1. United Kingdom Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Advanced Medical Solutions Group plc

Advanced Medical Solutions Group plc

282.00
GBX
-0.50
(-0.18%)
47.18BMarket Cap
Mar 17Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.29
0.3
0.33
0.4
0.46
0.48
0.48
0.4
0.5
0.57
0.58
0.83
1.06
- -
Basic EPS, GAAP
0.06
0.06
0.07
0.07
0.1
0.11
0.09
0.04
0.08
0.09
0.07
0.03
0.05
- -
Free Cash Flow per Basic Share
0.06
0.07
0.09
0.08
0.06
0.09
0.08
0.09
0.13
0.11
0.04
0.07
0.11
- -
Dividend per Share
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.02
0.02
0.03
- -
Book Value per Share
0.42
0.45
0.5
0.6
0.72
0.81
0.89
0.94
0.98
1.09
1.14
1.12
1.2
1.2
Tangible Book Value per Share
0.16
0.21
0.27
0.34
0.45
0.54
0.49
0.42
0.49
0.54
0.5
0.12
0.25
0.25
Basic Weighted Avg Shares
206
208
208
210
212
213
215
215
216
217
216
214
216
216
Sales/Revenue/Turnover
59
63
69
83
97
103
102
87
109
124
126
178
229
- -
Operating Margin (%)
23.07
24.08
24.84
23.38
26.05
28.14
24.71
13.32
21.18
20.02
14.96
12.47
12.43
- -
Depreciation Expense
2
3
3
3
3
4
6
7
9
9
11
16
21
- -
Net Income, GAAP
11
13
14
16
20
22
19
9
17
20
16
7
10
- -
Effective Tax Rate (%)
13.53
15.47
16.93
17.85
20.35
20.46
22.01
14.92
20.48
21.24
24.9
27.29
43.23
- -
Profit Margin (%)
19.1
20.42
20.58
18.85
20.78
21.92
18.48
9.89
16.1
16.41
12.59
4
4.35
- -
Working Capital
18
29
44
60
81
100
95
82
98
109
101
82
89
89
LT Debt
- -
- -
- -
- -
10
9
9
10
9
9
8
78
67
67
Total Equity
86
93
104
126
152
173
191
202
213
237
244
242
260
260
Return on Invested Capital (%)
13.5
14.17
14.29
13.54
13.76
12.9
9.71
4.38
8.38
8.34
5.66
2.8
3.81
- -
Return on Capital (%)
13.63
14.36
14.35
13.69
13.97
13.21
10.02
4.3
8.16
8.83
6.47
3.27
3.74
- -
Return on Common Equity (%)
14.23
14.36
14.36
13.69
14.49
13.84
10.4
4.36
8.43
9.08
6.61
2.93
3.99
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
9
13
15
LT Borrowings
67
60
57
LT Finance Leases
11
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
215
216
216
Market Capitalization
424
469
472

Working Capital

GBP

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
126
134
139
Cash, Cash Equivalents & STI
17
19
18
Accounts Receivable, Net
46
50
38
Inventories
55
62
70
Total Current Liabilities
44
47
50
Payables & Accruals
- -
- -
- -
ST Debt
9
13
15
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.85%
5.25%
7.7%
Free Cash Flow
11.36%
20.5%
62.3%
Net Income, GAAP
6.39%
16.64%
40.32%
Sales/Revenue/Turnover
13.89%
22.15%
28.96%
Total Cash Common Dividend
14.38%
11.68%
11.34%

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
126
2024
- -
- -
178
2025
- -
- -
229

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.07
2024
- -
- -
0.03
2025
- -
- -
0.05

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.02
2025
- -
- -
0.03

Company Description

Company Profile APIChatGPT
CEO
Andrew Christopher Meredith
Full Time Employees
1,800
Sector
Health technology
Industry
Medical specialties
Address
Premier Park Winsford CH United Kingdom CW7 3RT
IPO Date
Apr 30, 2002
Website
admedsol.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Advanced Medical Solutions Group plc is a UK-based developer, manufacturer and marketer of advanced wound care and surgical products focused on tissue-healing technologies. The company offers a broad portfolio including the ActivHeal range of wound dressings comprising hydrogels, hydrocolloids, foams and alginates; LiquiBand tissue adhesives and sealants for topical, large incision, microbial, surgical and internal applications; Resorba sutures and collagen-based products; biosurgical haemostats and absorbable implants from Syntacoll; Liquifix resorbable fixation systems; exudate management solutions; silver-impregnated infection control products such as silver hydrogels and alginates; and moisture-wicking fabrics with Tri-Go technology, serving hospitals, clinics and healthcare providers worldwide across more than 80 countries. Founded in 1993 and headquartered in Winsford, Cheshire, the group operates manufacturing and R&D facilities in 14 locations employing over 1,500 people, with primary revenue from its Surgical and Woundcare segments led by branded surgical products. In 2024, AMS completed the acquisitions of Syntacoll on March 1, enhancing its collagen-based absorbable surgical implants, and Peters Surgical on July 1 for up to EUR141.4 million following regulatory approval, significantly expanding its specialty sutures, mechanical haemostasis, internal cyanoacrylate devices and European market presence; these follow six prior acquisitions since 2019 including Sealantis, Biomatlante, Raleigh, AFS Medical and Connexicon, alongside the US launch of Liquifix atraumatic fixation devices and strategic Woundcare margin improvement initiatives.